Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending December 31, 2025 (JGAAP)
Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending December 31, 2025 (JGAAP)
Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending December 31, 2025 (JGAAP)
RaQualia Pharma, Jan-Sep (Cumulative 3Q) Ordinary Profit Loss Widens, Jul-Sep Ordinary Profit Turns to Loss
Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2025 (JGAAP)
RaQualia Pharma, First Half Ordinary Profit Loss Widens, Apr-Jun Ordinary Profit Loss Widens
Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2025 (JGAAP)
Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2025 (JGAAP)
Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2025 (JGAAP)
Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2025 (JGAAP)
Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2025 (JGAAP)
Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2025 (JGAAP)
Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2025 (JGAAP)
Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2025 (JGAAP)
Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2025 (JGAAP)
RaQualia Pharma, Jan-Mar (1Q) Ordinary Profit Turns to Profit
Summary of Consolidated Financial Results for the Fiscal Year Ended December 31, 2024 (JGAAP)
RaQualia Pharma, Returning to Profitability This Year
RaQualia Pharma, The Current Fiscal Year Ordinary Profit Revised Downward to a Loss
RaQualia Pharma Inc., July-September (3Q) Ordinary Profit Turns to Profit